Literature DB >> 8016844

Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis.

A B Begovich1, W Klitz, P V Moonsamy, J Van de Water, G Peltz, M E Gershwin.   

Abstract

Nonradioactive sequence-specific oligonucleotide probes for the polymorphic HLA class II genes have been used to type samples from 51 Caucasian patients with the autoimmune liver disease, primary biliary cirrhosis, and 240 Caucasian controls. Although the allelic distribution at the DPB1 locus showed no significant variation between patients and controls, there was heterogeneity in the distribution of DR-DQ haplotypes where the frequency of the DRB1*0801-DQA1*0401/0601-DQB1*04 haplotype was significantly increased in the patients, suggesting it confers susceptibility to this disease. Two other haplotypes, DRB1*1501-DQA1*0102-DQB1*0602 and DRB1*1302-DQA1*0102-DQB1*0604, were significantly reduced in the patients, suggesting they confer protection. Tests of the individual loci show that resistance to this disease is most strongly associated with the DQA1*0102 allele shared by both protective haplotypes. Due to linkage disequilibrium it is unclear whether multiple genes or a single locus on the susceptible DR8 haplotype are needed for predisposition. These data show that distinct HLA class II alleles confer both predisposition and resistance to PBC and provide insight into the role that these genes may play in the immunopathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016844     DOI: 10.1111/j.1399-0039.1994.tb02303.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  18 in total

1.  Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies.

Authors:  Owen D Solberg; Steven J Mack; Alex K Lancaster; Richard M Single; Yingssu Tsai; Alicia Sanchez-Mazas; Glenys Thomson
Journal:  Hum Immunol       Date:  2008-06-09       Impact factor: 2.850

Review 2.  Genetics and genomics of primary biliary cirrhosis.

Authors:  Brian D Juran; Konstantinos N Lazaridis
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

3.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

Review 4.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

5.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 6.  Genetic and epigenetic influences on the loss of tolerance in autoimmunity.

Authors:  Peng Zhang; Qianjin Lu
Journal:  Cell Mol Immunol       Date:  2018-03-05       Impact factor: 11.530

Review 7.  Primary biliary cholangitis: pathogenesis and therapeutic opportunities.

Authors:  Aliya F Gulamhusein; Gideon M Hirschfield
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-09       Impact factor: 46.802

8.  Familial clustering and genetic background of primary biliary cirrhosis in Japan.

Authors:  Masatoshi Yanagisawa; Hitoshi Takagi; Hitomi Takahashi; Masahiro Uehara; Toshiyuki Otsuka; Kazuhisa Yuasa; Kenichi Hosonuma; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2009-12-11       Impact factor: 3.199

9.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

Review 10.  Genome-Wide Association Studies in Primary Biliary Cirrhosis.

Authors:  Aliya F Gulamhusein; Brian D Juran; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2015-12-16       Impact factor: 6.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.